The interaction between procarbazine and γ-radiation on animal survival and on cell proliferation in the jejunum of the mouse was investigated. Procarbazine (501 mg/kg) injected intraperitoneally enhanced the effect of the gastrointestinal radiation syndrome in whole-body lethality studies by reducing the 7-day LD50 by 269 rads. Similar lethality responses were noted whether the drug was administered immediately before or after irradiation. In a series of temporal response studies, 501 mg/kg procarbazine injected intraperitoneally affected intestinal crypt cell proliferative activity in a manner similar to the effect of 1,000 rads of γ-radiation, by an increase to above-normal proliferative activity. The indices of proliferative activity employed were tritiated thymidine activity per milligram intestine, tritiated thymidine activity per crypt, labeled nuclei per crypt, and mitotic figures per crypt. When procarbazine was injected 15 min prior to irradiation, the crypt cell proliferative activity decreased but never recovered, thus indicating an enhanced response with combined treatment.

Keywords:
Radiation effects, Intestine, Procarbazine, Cell kinetics, Antineoplastic, Radiation sensitizers
This content is only available via PDF.
© 1978 S. Karger AG, Basel
1978
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.